Nanoform Finland Oyj (STO:NANOFS)
Sweden · Delayed Price · Currency is SEK 8.82
-0.20 (-2.22%)
At close: Feb 9, 2026
Nanoform Finland Oyj Revenue
Nanoform Finland Oyj had revenue of 662.00K EUR in the quarter ending September 30, 2025, a decrease of -14.47%. This brings the company's revenue in the last twelve months to 3.84M, up 58.20% year-over-year. In the year 2024, Nanoform Finland Oyj had annual revenue of 3.66M with 42.70% growth.
Revenue (ttm)
3.84M EUR
Revenue Growth
+58.20%
P/S Ratio
17.68
Revenue / Employee
22.20K EUR
Employees
173
Market Cap
750.80M SEK
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.66M | 1.10M | 42.70% |
| Dec 31, 2023 | 2.57M | -920.89K | -26.41% |
| Dec 31, 2022 | 3.49M | 1.53M | 78.42% |
| Dec 31, 2021 | 1.95M | 1.25M | 178.38% |
| Dec 31, 2020 | 702.12K | 421.69K | 150.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioInvent International AB | 244.85M |
| Genovis AB (publ.) | 117.66M |
| Oncopeptides AB | 62.47M |
| Corline Biomedical AB | 8.88M |
| Medivir AB | 3.88M |
| Xspray Pharma AB | 3.81M |
| Infant Bacterial Therapeutics AB | -1.00K |
| FluoGuide | -703.14K |